Hi,
M. Mamas et al. mentioned as:
"..., to date no biomarker that has been identified through metabolomics is in routine use in clinical practice."
Mamas, Mamas, et al. "The role of metabolites and metabolomics in clinically applicable biomarkers of disease." Archives of toxicology 85.1 (2011): 5-17. (http://link.springer.com/article/10.1007/s00204-010-0609-6)
Are there any update (clinical application)?
Thanks.
As a new Biomarker, yet to materialise. However, there are many new proposed ones. But it needs to pass the test of time and reproducibility. I would be also interested if anyone else came across one with good potentials.
the problem is 'clinical routine'. It is really difficult to get legal approvals (e.g. in the United States, FDA), and to convince insurance companies to cover costs. Easily a decade, even if everything is perfect. Multiple studies on various cohorts of patients are needed before a clinical organization would consider discussing the topic, after meta-analysis (comparison) of those study outcomes.